GlassScriptPhysician profile
Gregory D Olds
NPI 1972671428
$9,813.29
in general payments reported to CMS, 2019-2025
39 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $313 · 2021: $452 · 2022: $1,607 · 2023: $2,609 · 2024: $2,321 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,474 · Consulting Fee: $1,890 · Education: $69.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,474.48 |
| Consulting Fee | $1,890.00 |
| Education | $69.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,506.05 | 2019-2025 | |
| Olympus Corporation | $1,890.00 | 2022-2023 | |
| Olympus Medical Systems Corporation | $840.00 | 2024 | |
| Janssen Biotech, INC. | $523.72 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $415.23 | 2019-2025 | Xifaxan, Trulance |
| Ucb, INC. | $365.70 | 2019-2020 | |
| Pfizer INC. | $335.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $318.45 | 2019-2025 | Entyvio, Eohilia |
| Ferring Pharmaceuticals INC. | $316.32 | 2019-2024 | Rebyota |
| Celgene Corporation | $267.55 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $218.22 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $203.69 | 2021-2025 | Spyglass, Speedband Superview Super 7, Axios |
| Celltrion USA INC. | $168.36 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $145.58 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $141.45 | 2024-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $140.53 | 2022-2025 | Dupixent |
| Olympus America INC. | $121.37 | 2019 | |
| Aimmune Therapeutics, INC. | $80.09 | 2024-2025 | Zenpep |
| Endogastric Solutions, INC | $80.02 | 2021-2023 | Esophyx |
| Ironwood Pharmaceuticals, INC | $78.90 | 2020-2024 | Linzess |
| Enterra Medical, INC. | $70.73 | 2025 | |
| Nestle Healthcare Nutrition INC. | $67.06 | 2022-2023 | |
| Madrigal Pharmaceuticals | $60.34 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $56.46 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $50.85 | 2020-2024 | |
| Vivus LLC | $43.63 | 2022-2024 | Pancreaze, Qsymia |
| Redhill Biopharma INC. | $40.42 | 2022-2023 | Movantik, Aemcolo, Talicia |
| Lilly USA, LLC | $39.78 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $31.99 | 2024-2025 | Voquezna |
| Amgen INC. | $31.25 | 2023 | Amjevita, Avsola |
| Shionogi INC | $25.90 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.94 | 2025 | Givlaari |
| Medtronic, INC. | $20.02 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $20.00 | 2024 | Bylvay, Iqirvo |
| Organon LLC | $15.42 | 2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $15.15 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.70 | 2024 | Cyltezo |
| Exact Sciences Corporation | $14.10 | 2023 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $13.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Olds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.